Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T., Rustin, G., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A., Jayson, G. C., Stark, D., Swart, A. M., Farrelly, L., Kaplan, R., Parmar, M. K. B., Perren, T. J., & , (n.d.). standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet oncology, 16(8), 928–936. http://access.bl.uk/ark:/81055/vdc_100051209030.0x00002d